Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the
KPTI: Karyopharm Therapeutics Inc.
2020-06-22 11:25:10
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2020-06-22 11:25:10
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)